Lv12
16 积分 2022-01-24 加入
Molecular glue meets antibody: next-generation antibody–drug conjugates
3小时前
待确认
Degrader-antibody conjugates
3小时前
已完结
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models
6小时前
已完结
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
1个月前
已完结
Routes to molecular glue degrader discovery
2个月前
已完结
The Expanding E3 Ligase-Ligand Landscape for PROTAC Technology
2个月前
已完结
A mechanistic pharmacokinetic-pharmacodynamic model for degrader-antibody conjugates
2个月前
已完结
Rational engineering of degradation tail-driven CELMoD–antibody conjugates for precision malignancy therapy
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4个月前
已完结
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
8个月前
已完结
皖公网安备34019202002308
